Best Researcher Award
| William Figg | |
|---|---|
| Affiliation | National Cancer Institute |
| Country | United States |
| Scopus ID | 35377337900 |
| Documents | 883 |
| Citations | 48,614 |
| h-index | 115 |
| Subject Area | Pharmacology |
| Event | International Popular Scientist Awards |
| ORCID | 0000-0003-2428-5613 |
William Figg
National Cancer Institute
William Figg the Best Researcher Award recognizes sustained excellence in scientific investigation, scholarly publication, and contributions to advancing biomedical knowledge. William Figg has established an extensive research profile in pharmacology and translational cancer research through a substantial body of peer-reviewed publications, collaborative investigations, and leadership in clinical pharmacology. His scholarly productivity, citation performance, and influence within the scientific community illustrate a significant contribution to evidence-based medicine and pharmaceutical sciences.[1]
Contents
Abstract
William Figg’s academic career reflects long-term engagement in pharmacology, oncology, and clinical translational research. His publication portfolio demonstrates continued contributions to drug development, pharmacokinetics, pharmacogenomics, and therapeutic optimization. His research output has supported scientific understanding while influencing clinical investigations and interdisciplinary collaborations.[1]
Keywords
Pharmacology, Clinical Pharmacology, Oncology Research, Drug Development, Translational Medicine, Precision Medicine, Cancer Therapeutics, Pharmacogenomics, Biomedical Research, Clinical Trials.
Introduction
Modern pharmacological research requires rigorous experimental design, interdisciplinary collaboration, and continuous translation of laboratory discoveries into clinical practice. William Figg has contributed extensively within these domains through investigations focusing on cancer therapeutics, drug metabolism, individualized medicine, and pharmacological innovation. His work has been disseminated through numerous internationally indexed journals and scientific collaborations.[2]
Research Profile
Research Contributions
William Figg has contributed to investigations involving pharmacokinetics, pharmacogenomics, anti-cancer drug evaluation, biomarker discovery, precision medicine, and optimization of therapeutic regimens. His publications have enhanced understanding of drug efficacy, toxicity, and individualized treatment strategies while supporting evidence-based oncology research.[3]
Publications
Research Impact
A citation count exceeding forty-eight thousand and an h-index above one hundred indicate broad scholarly recognition across pharmacology and biomedical sciences. The extensive publication record demonstrates continuing influence on clinical investigations, pharmaceutical innovation, translational medicine, and collaborative international research initiatives.[1]
Award Suitability
William Figg’s academic achievements align with the objectives of the International Popular Scientist Awards by demonstrating consistent scientific productivity, measurable research impact, interdisciplinary collaboration, and sustained advancement of pharmacological science. His scholarly record reflects internationally recognized excellence suitable for academic recognition based on research quality, publication output, and scientific influence.[2]
Conclusion
William Figg has established a distinguished research profile characterized by extensive scholarly publications, significant citation impact, and meaningful contributions to pharmacology and cancer research. These accomplishments collectively illustrate a sustained commitment to advancing biomedical science and support recognition through the Best Researcher Award.[1]
External Links
References
- Elsevier. (n.d.). Scopus author details: William Figg, Author ID 35377337900. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=35377337900 - ORCID. (n.d.). William Figg ORCID Profile.
https://orcid.org/0000-0003-2428-5613 - National Center for Biotechnology Information. Representative publication with DOI.
- Staton, A., Abel, M., & Figg, W. D. (2026). Targeting the PI3K/AKT pathway in prostate cancer: The role of PTEN deficiency and biomarker-guided therapy. Cancer Biology & Therapy.